The short version
22 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Bortezomib
Bortezomib · BORTEZOMIB 1 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous; Subcutaneous · Gland Pharma Limited
NDC 68083-0650-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $846.17 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA219167
- TE code
- AP
- Approval date
- Jan 6, 2026
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Bortezomib (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| BluePoint Laboratories | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Eugia US LLC | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Apotex Corp | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Avenacy, LLC | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| BluePoint Laboratories | BORTEZOMIB 3.5 mg/3.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Dr.Reddy's Laboratories, Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | BORTEZOMIB 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | BORTEZOMIB 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | BORTEZOMIB 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | BORTEZOMIB 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Meitheal Pharmaceuticals Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ningbo Shuangcheng Pharmaceutical Co., Ltd. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NorthStar RxLLC | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | BORTEZOMIB 3.5 mg/3.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Pharmascience Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sintetica US LLC | BORTEZOMIB 3.5 mg/3.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Somerset Therapeutics LLC | BORTEZOMIB 3.5 mg/3.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Takeda Pharmaceuticals America, Inc. | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Waverley Pharma Inc | BORTEZOMIB 3.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | BORTEZOMIB 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | BORTEZOMIB 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Bortezomib — NDC 68083-0650-01," retrieved September 3, 2026, https://drugdashboards.com/drug/68083065001.
Free to cite with attribution — see how the data is put together.